Immune globulin (human) 10 % liquid: A review of its use in primary immunodeficiency disorders

BioDrugs

Volumn 27, Issue 4, 2013, Pages 393-400

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GAMMAKED; GAMUNEX C; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ARTICLE; ASEPTIC MENINGITIS; ASTHMA; BACTERIAL INFECTION; CHILL; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLUSHING; HEADACHE; HEART RATE; HOME CARE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; LIMB PAIN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RIGOR; SIDE EFFECT; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UPPER ABDOMINAL PAIN; URTICARIA; VERTIGO; VOMITING;

EID: 84880844086     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0044-3     Document Type: Article

References (31)

1. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255-63.
2. Haddad É, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci. 2012;46(3):315-21.
3. Hernandez-Trujillo HS, Chapel H, Lo Re V 3rd, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169(1):57-69.
4. Notarangelo LD, Fischer A, Geha RS, et al. International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161-78.
5. Merck & Co. The Merck Manual for health care professionals: immunodeficiency disorders; 2010. http://www.merckmanuals.com/professional/ immunology-allergic-disorders/immunodeficiency-disorders/overview-of- immunodeficiency-disorders.html. Accessed 10 Apr 2013.
6. Al-Tamemi S, Elnour I, Dennison D. Primary immunodeficiency diseases in Oman: five years' experience at Sultan Qaboos University Hospital. World Allergy Organ J. 2012;5(5):52-6.
7. Gathmann B, Grimbacher B, Beauté J, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol. 2009;157(Suppl 1):3-11.
8. Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27(5):517-24.
9. Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med. 2010;122(5):176-84.
10. Baxter Healthcare. Gammagard Liquid [immune globulin infusion (human)] 10%: US prescribing information; 2012. http://www.baxter.com/products/ biopharmaceuticals/downloads/gamliquid-PI.pdf. Accessed 10 Apr 2013.
11. European Medicines Agency. Kiovig (human normal immunoglobulin) 100 mg/mL solution for infusion: summary of product characteristics; 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000628/WC500043416.pdf. Accessed 10 Apr 2013.
12. Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21-30.
13. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354-60 e4.
14. Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315-22.
15. Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169(2):172-81.
16. Krusius T, Tuimala J, Tenkanen H. Isoagglutinin titres vary in different brands of IV-immunoglobulins [abstract]. Vox Sang. 2011;101:176-7.
17. Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26(4):388-95.
18. Björkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90(4):286-93.
19. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323-31.
20. US FDA. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency; 2008. http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm072130.htm. Accessed 10 Apr 2013.
21. Kallenberg CGM. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin Exp Immunol. 2007;150(3):437-41.
22. Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;33(Suppl 2):S90-4.
23. Grifols Therapeutics Inc. Gamunex®-C (immune globulin injection [human] 10% caprylate/chromatography purified): US prescribing information; 2012. http://www.talecris-pi.info/inserts/gamunex.pdf. Accessed 10 Apr 2013.
24. Kedrion Biopharma. Gammaked™ (immune globulin injection [human] 10% caprylate/chromatography purified): US prescribing information; 2011. http://www.gammaked.com/filebin/pdf/gammaked-prescribing-information.pdf. Accessed 10 Apr 2013.
25. CSL Behring LLC. Hizentra® (immune globulin subcutaneous [human] 20% liquid): US prescribing information; 2011. http://labeling.cslbehring.com/PI/US/ Hizentra/EN/Hizentra-Prescribing-Information.pdf. Accessed 10 Apr 2013.
26. CSL Behring LLC. Vivaglobin® (immune globulin subcutaneous [human] 16% liquid): US prescribing information; 2010. http://labeling.cslbehring.com/ PI/US/Vivaglobin/EN/Vivaglobin-Prescribing-Information.pdf. Accessed 10 Apr 2013.
27. CSL Behring LLC. Letter to healthcare professionals. Re: United States only - important information about Vivaglobin®; 2011. http://www. vivaglobinaccess.com/. Accessed 10 Apr 2013.
28. Melamed I, Testori A, Spirer Z. Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease. Int Rev Immunol. 2012;31(6):451-61.
29. Garcia-Lloret M, McGhee S, Chatila T. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am. 2008;28(4):833-49.
30. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6(6):434-42.
31. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345(8946):365-9.